Abstract
Introduction: Some models of therapy for neurodegenerative diseases envision starting treatment before symptoms develop. Demonstrating that such treatments are effective requires accurate knowledge of when symptoms would have started without treatment. Familial frontotemporal lobar degeneration offers a unique opportunity to develop predictors of symptom onset. Methods: We created dementia risk scores in 268 familial frontotemporal lobar degeneration family members by entering covariate-adjusted standardized estimates of brain atrophy into a logistic regression to classify asymptomatic versus demented participants. The score's predictive value was tested in a separate group who were followed up longitudinally (stable vs. converted to dementia) using Cox proportional regressions with dementia risk score as the predictor. Results: Cross-validated logistic regression achieved good separation of asymptomatic versus demented (accuracy = 90%, SE = 0.06). Atrophy scores predicted conversion from asymptomatic or mildly/questionably symptomatic to dementia (HR = 1.51, 95% CI: [1.16,1.98]). Discussion: Individualized quantification of baseline brain atrophy is a promising predictor of progression in asymptomatic familial frontotemporal lobar degeneration mutation carriers.
Original language | English (US) |
---|---|
Pages (from-to) | 37-48 |
Number of pages | 12 |
Journal | Alzheimer's and Dementia |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2020 |
Externally published | Yes |
Keywords
- Frontotemporal dementia
- Genetics
- Magnetic resonance imaging (MRI)
- TDP-43
- Tau
ASJC Scopus subject areas
- Clinical Neurology
- Geriatrics and Gerontology
- Psychiatry and Mental health
- Cellular and Molecular Neuroscience
- Health Policy
- Developmental Neuroscience
- Epidemiology
Fingerprint
Dive into the research topics of 'Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Alzheimer's and Dementia, Vol. 16, No. 1, 01.01.2020, p. 37-48.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration
AU - on behalf of the ARTFL/LEFFTDS consortium
AU - Staffaroni, Adam M.
AU - Cobigo, Yann
AU - Goh, Sheng Yang M.
AU - Kornak, John
AU - Bajorek, Lynn
AU - Chiang, Kevin
AU - Appleby, Brian
AU - Bove, Jessica
AU - Bordelon, Yvette
AU - Brannelly, Patrick
AU - Brushaber, Danielle
AU - Caso, Christina
AU - Coppola, Giovanni
AU - Dever, Reilly
AU - Dheel, Christina
AU - Dickerson, Bradford C.
AU - Dickinson, Susan
AU - Dominguez, Sophia
AU - Domoto-Reilly, Kimiko
AU - Faber, Kelly
AU - Ferrall, Jessica
AU - Fields, Julie A.
AU - Fishman, Ann
AU - Fong, Jamie
AU - Foroud, Tatiana
AU - Forsberg, Leah K.
AU - Gavrilova, Ralitza
AU - Gearhart, Debra
AU - Ghazanfari, Behnaz
AU - Ghoshal, Nupur
AU - Goldman, Jill
AU - Graff-Radford, Jonathan
AU - Graff-Radford, Neill
AU - Grant, Ian
AU - Grossman, Murray
AU - Haley, Dana
AU - Heuer, Hilary W.
AU - Hsiung, Ging Yuek
AU - Huey, Edward D.
AU - Irwin, David J.
AU - Jones, David T.
AU - Jones, Lynne
AU - Kantarci, Kejal
AU - Karydas, Anna
AU - Kaufer, Daniel I.
AU - Kerwin, Diana R.
AU - Knopman, David S.
AU - Kraft, Ruth
AU - Kramer, Joel H.
AU - Kremers, Walter K.
N1 - Funding Information: Conflict of interest: A.M.S. received research support from the Larry H. Hillblom foundation and support from the NIH. Y.C., S.-Y.M.G., L.B., R.D., K.C., J.B., D.B., C.D., R.D., J.F., D.G., D.H., L.J., A.K., R.K., M.L., P.A.L., M.M., E.R., P.S., J.S., and J.T., had nothing to disclose. J.K. had provided expert witness testimony for Teva Pharmaceuticals in Forest Laboratories Inc. et al. v. Teva Pharmaceuticals USA, Inc., Case Nos. 1:14-cv-00121 and 1:14-cv-00686 (D. Del. filed Jan. 31, 2014 and May 30, 2014) regarding the drug Memantine; for Apotex/HEC/Ezra in Novartis AG et al. v. Apotex Inc., No. 1:15-cv-975 (D. Del. filed Oct. 26, 2015, regarding the drug Fingolimod. He had also given testimony on behalf of Puma Biotechnology in Hsingching Hsu et al., vs. Puma Biotechnology, INC., et al. 2018 regarding the drug neratinib. He received research support from the NIH. B.A. received research support from the CDC. P.B. was employed by the Rainwater Charitable Foundation. G.C., B.C.D., K.F., J.A.F., T.F., L.K.F., R.G., J.G.-R., H.W.H., E.D.H., W.A.K., D.L., B.L.M., L.P., M.P., K.P.R., K.R., L.M.S., S.W., and B.W. received research support from the NIH. J.H.K. receives research support from NIH, the Tau Consortium, and the Larry H. Hillblom Foundation, and provides consultation for Biogen. S.D. was on staff at the Association for Frontotemporal Degeneration and a member of the National Institute for Neurological Disorders and Stroke Advisory Council. N.G. had participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) trial. She received research support from Tau Consortium and Association for Frontotemporal Dementia and is funded by the NIH. J.S.G. served as a consultant to the Novartis Alzheimer's Prevention Advisory Board. She received research support from the NIH, HDSA, New York State Department of Health (RFA # 1510130358). N.G.-R. received royalties from UpToDate and had participated in multicenter therapy studies sponsored by Biogen, TauRx, AbbVie, Novartis, and Lilly. He received research support from the NIH. M.G. received grant support from the NIH, Avid, and Piramal; participated in clinical trials sponsored by Biogen, TauRx, and Alector; served as a consultant to Bracco and UCB; and served on the Editorial Board of Neurology. G.-Y.H. had served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly, and Roche/Genentech. He received research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. D.J.I. received support from the NIH, Brightfocus Foundation, and Penn Institute on Aging. D.T.J. received research support from the NIH and the Minnesota Partnership for Biotechnology and Medical Genomics. K.K. served on the Data Safety Monitoring Board for Takeda Global Research & Development Center, Inc.; data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy; research support from the Avid Radiopharmaceuticals, Eli Lilly, the Alzheimer's Drug Discovery Foundation, and the NIH. D.R.K. has served on an Advisory Board for AbbVie and as site PI for studies funded by Roche/Genentech, AbbVie, Avid, Novartis, Eisai, Eli Lilly, and UCSF. D.S.K. served on the DSMB of the DIAN-TU study, is a site PI for clinical trials sponsored by Biogen, Lilly and the University of Southern California, and is funded by the NIH. W.K.K. received research funding from AstraZeneca, Biogen, Roche, DOD, and the NIH. I.L. received research support from the NIH, Parkinson Study Group, Parkinson Foundation, Michael J Fox Foundation, AVID Pharmaceuticals, C2N Diagnostics/Abbvie, and Bristol-Myers Squibb. She was a member of the Biogen and Bristol-Myers Squibb Advisory Boards, Biotie/Parkinson Study Group Medical Advisory Board, and consultant for Toyama Pharmaceuticals. She received salary from the University of California San Diego and as Editor in Frontiers in Neurology. C.L. received honoraria for editorial work from Elsevier, Inc. I.R.M. received research funding from the Canadian Institutes of Health Research. S.M.M. served as an investigator for clinical trials sponsored by AbbVie, Allon Therapeutics, Biogen, Bristol-Myers Squibb, C2N Diagnostics, Eisai Inc., Eli Lilly and Co., Genentech, Janssen Pharmaceuticals, Medivation, Merck, Navidea Biopharmaceuticals, Novartis, Pfizer, and TauRx Therapeutics. He received research support from the NIH. C.O. received research funding from the NIH, the CIHR, and Biogen, Inc. He was also supported by the Jane Tanger Black Fund for Young-Onset Dementias, the Nancy H. Hall Fund for Geriatric Psychiatry, and the gift from Joseph Trovato. R.P. was employed by the Bluefield Project. R.R. received research funding from the NIH and the Bluefield Project to Cure Frontotemporal Dementia. E.D.R. received research support from the NIH, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer's Association, BrightFocus Foundation, Biogen, Alector, and owns intellectual property related to tau. N.T. was employed by the Association for Frontotemporal Degeneration. A.T. received research support from the NIH and the Alzheimer's Association. J.Q.T. may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is a coinventor and he received revenue from the sale of Avid to Eli Lily as a coinventor on Aβ amyloid imaging–related patents submitted by the University of Pennsylvania. He received research support from the NIH and several nonprofits. Z.W. was supported by the NIH, Mayo Clinic Center for Regenerative Medicine, the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch, the Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. He has also received grant funding support from Allergan, Inc. (educational grant), and Abbvie (medication trials). A.L.B. received research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association. He served as a consultant for Aeton, Abbvie, Alector, Amgen, Arkuda, Ionis, Iperian, Janssen, Merck, Novartis, Samumed, Toyama and UCB, and received research support from Avid, Biogen, BMS, C2N, Cortice, Eli Lilly, Forum, Genentech, Janssen, Novartis, Pfizer, Roche, and TauRx. B.F.B. served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He received royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017). He served on the Scientific Advisory Board of the Tau Consortium. He received research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. H.J.R. received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience and Ionis Pharmaceuticals, and receives research support from the NIH.The authors extend their appreciation to Drs. John Hsiao and Dallas Anderson from the National Institute on Aging, Drs. Marg Sutherland and Codrin Lungu from the National Institute of Neurological Disorders and Stroke, the staff of all centers, and particularly to our patients and their families for their participation in this protocol. This work is supported by the National Institutes of Health [grants AG045390, NS092089, AG032306, AG021886, AG016976, and K24AG045333] and the Larry L. Hillblom Foundation [2018-A-025-FEL]. Samples from the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. Conflict of interest: A.M.S. received research support from the Larry H. Hillblom foundation and support from the NIH. Y.C., S.-Y.M.G., L.B., R.D., K.C., J.B., D.B., C.D., R.D., J.F., D.G., D.H., L.J., A.K., R.K., M.L., P.A.L., M.M., E.R., P.S., J.S., and J.T., had nothing to disclose. J.K. had provided expert witness testimony for Teva Pharmaceuticals in Forest Laboratories Inc. et al. v. Teva Pharmaceuticals USA, Inc., Case Nos. 1:14-cv-00121 and 1:14-cv-00686 (D. Del. filed Jan. 31, 2014 and May 30, 2014) regarding the drug Memantine; for Apotex/HEC/Ezra in Novartis AG et al. v. Apotex Inc., No. 1:15-cv-975 (D. Del. filed Oct. 26, 2015, regarding the drug Fingolimod. He had also given testimony on behalf of Puma Biotechnology in Hsingching Hsu et al., vs. Puma Biotechnology, INC., et al. 2018 regarding the drug neratinib. He received research support from the NIH. B.A. received research support from the CDC. P.B. was employed by the Rainwater Charitable Foundation. G.C., B.C.D., K.F., J.A.F., T.F., L.K.F., R.G., J.G.-R., H.W.H., E.D.H., W.A.K., D.L., B.L.M., L.P., M.P., K.P.R., K.R., L.M.S., S.W., and B.W. received research support from the NIH. J.H.K. receives research support from NIH, the Tau Consortium, and the Larry H. Hillblom Foundation, and provides consultation for Biogen. S.D. was on staff at the Association for Frontotemporal Degeneration and a member of the National Institute for Neurological Disorders and Stroke Advisory Council. N.G. had participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) trial. She received research support from Tau Consortium and Association for Frontotemporal Dementia and is funded by the NIH. J.S.G. served as a consultant to the Novartis Alzheimer's Prevention Advisory Board. She received research support from the NIH, HDSA, New York State Department of Health (RFA # 1510130358). N.G.-R. received royalties from UpToDate and had participated in multicenter therapy studies sponsored by Biogen, TauRx, AbbVie, Novartis, and Lilly. He received research support from the NIH. M.G. received grant support from the NIH, Avid, and Piramal; participated in clinical trials sponsored by Biogen, TauRx, and Alector; served as a consultant to Bracco and UCB; and served on the Editorial Board of Neurology. G.-Y.H. had served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly, and Roche/ Genentech. He received research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. D.J.I. received support from the NIH, Brightfocus Foundation, and Penn Institute on Aging. D.T.J. received research support from the NIH and the Minnesota Partnership for Biotechnology and Medical Genomics. K.K. served on the Data Safety Monitoring Board for Takeda Global Research & Development Center, Inc.; data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy; research support from the Avid Radiopharmaceuticals, Eli Lilly, the Alzheimer's Drug Discovery Foundation, and the NIH. D.R.K. has served on an Advisory Board for AbbVie and as site PI for studies funded by Roche/ Genentech, AbbVie, Avid, Novartis, Eisai, Eli Lilly, and UCSF. D.S.K. served on the DSMB of the DIAN-TU study, is a site PI for clinical trials sponsored by Biogen, Lilly and the University of Southern California, and is funded by the NIH. W.K.K. received research funding from AstraZeneca, Biogen, Roche, DOD, and the NIH. I.L. received research support from the NIH, Parkinson Study Group, Parkinson Foundation, Michael J Fox Foundation, AVID Pharmaceuticals, C2N Diagnostics/ Abbvie, and Bristol-Myers Squibb. She was a member of the Biogen and Bristol-Myers Squibb Advisory Boards, Biotie/Parkinson Study Group Medical Advisory Board, and consultant for Toyama Pharmaceuticals. She received salary from the University of California San Diego and as Editor in Frontiers in Neurology. C.L. received honoraria for editorial work from Elsevier, Inc. I.R.M. received research funding from the Canadian Institutes of Health Research. S.M.M. served as an investigator for clinical trials sponsored by AbbVie, Allon Therapeutics, Biogen, Bristol-Myers Squibb, C2N Diagnostics, Eisai Inc., Eli Lilly and Co., Genentech, Janssen Pharmaceuticals, Medivation, Merck, Navidea Biopharmaceuticals, Novartis, Pfizer, and TauRx Therapeutics. He received research support from the NIH. C.O. received research funding from the NIH, the CIHR, and Biogen, Inc. He was also supported by the Jane Tanger Black Fund for Young-Onset Dementias, the Nancy H. Hall Fund for Geriatric Psychiatry, and the gift from Joseph Trovato. R.P. was employed by the Bluefield Project. R.R. received research funding from the NIH and the Bluefield Project to Cure Frontotemporal Dementia. E.D.R. received research support from the NIH, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer's Association, BrightFocus Foundation, Biogen, Alector, and owns intellectual property related to tau. N.T. was employed by the Association for Frontotemporal Degeneration. A.T. received research support from the NIH and the Alzheimer's Association. J.Q.T. may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is a coinventor and he received revenue from the sale of Avid to Eli Lily as a coinventor on Aβ amyloid imaging–related patents submitted by the University of Pennsylvania. He received research support from the NIH and several nonprofits. Z.W. was supported by the NIH, Mayo Clinic Center for Regenerative Medicine, the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch, the Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. He has also received grant funding support from Allergan, Inc. (educational grant), and Abbvie (medication trials). A.L.B. received research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association. He served as a consultant for Aeton, Abbvie, Alector, Amgen, Arkuda, Ionis, Iperian, Janssen, Merck, Novartis, Samumed, Toyama and UCB, and received research support from Avid, Biogen, BMS, C2N, Cortice, Eli Lilly, Forum, Genentech, Janssen, Novartis, Pfizer, Roche, and TauRx. B.F.B. served as an investigator for clinical trials sponsored by GE Healthcare and Axovant. He received royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017). He served on the Scientific Advisory Board of the Tau Consortium. He received research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and the Little Family Foundation. H.J.R. received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience and Ionis Pharmaceuticals, and receives research support from the NIH. Funding Information: The authors extend their appreciation to Drs. John Hsiao and Dallas Anderson from the National Institute on Aging, Drs. Marg Sutherland and Codrin Lungu from the National Institute of Neurological Disorders and Stroke, the staff of all centers, and particularly to our patients and their families for their participation in this protocol. This work is supported by the National Institutes of Health [grants AG045390, NS092089, AG032306, AG021886, AG016976, and K24AG045333] and the Larry L. Hillblom Foundation [2018-A-025-FEL]. Samples from the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. Funding Information: This work is supported by the National Institutes of Health [grants AG045390 , NS092089 , AG032306 , AG021886 , AG016976 , and K24AG045333 ] and the Larry L. Hillblom Foundation [2018-A-025-FEL]. Samples from the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. Publisher Copyright: © 2019 The Authors. Alzheimer's & Dementia published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Introduction: Some models of therapy for neurodegenerative diseases envision starting treatment before symptoms develop. Demonstrating that such treatments are effective requires accurate knowledge of when symptoms would have started without treatment. Familial frontotemporal lobar degeneration offers a unique opportunity to develop predictors of symptom onset. Methods: We created dementia risk scores in 268 familial frontotemporal lobar degeneration family members by entering covariate-adjusted standardized estimates of brain atrophy into a logistic regression to classify asymptomatic versus demented participants. The score's predictive value was tested in a separate group who were followed up longitudinally (stable vs. converted to dementia) using Cox proportional regressions with dementia risk score as the predictor. Results: Cross-validated logistic regression achieved good separation of asymptomatic versus demented (accuracy = 90%, SE = 0.06). Atrophy scores predicted conversion from asymptomatic or mildly/questionably symptomatic to dementia (HR = 1.51, 95% CI: [1.16,1.98]). Discussion: Individualized quantification of baseline brain atrophy is a promising predictor of progression in asymptomatic familial frontotemporal lobar degeneration mutation carriers.
AB - Introduction: Some models of therapy for neurodegenerative diseases envision starting treatment before symptoms develop. Demonstrating that such treatments are effective requires accurate knowledge of when symptoms would have started without treatment. Familial frontotemporal lobar degeneration offers a unique opportunity to develop predictors of symptom onset. Methods: We created dementia risk scores in 268 familial frontotemporal lobar degeneration family members by entering covariate-adjusted standardized estimates of brain atrophy into a logistic regression to classify asymptomatic versus demented participants. The score's predictive value was tested in a separate group who were followed up longitudinally (stable vs. converted to dementia) using Cox proportional regressions with dementia risk score as the predictor. Results: Cross-validated logistic regression achieved good separation of asymptomatic versus demented (accuracy = 90%, SE = 0.06). Atrophy scores predicted conversion from asymptomatic or mildly/questionably symptomatic to dementia (HR = 1.51, 95% CI: [1.16,1.98]). Discussion: Individualized quantification of baseline brain atrophy is a promising predictor of progression in asymptomatic familial frontotemporal lobar degeneration mutation carriers.
KW - Frontotemporal dementia
KW - Genetics
KW - Magnetic resonance imaging (MRI)
KW - TDP-43
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=85065448095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065448095&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2019.04.007
DO - 10.1016/j.jalz.2019.04.007
M3 - Article
C2 - 31272932
AN - SCOPUS:85065448095
SN - 1552-5260
VL - 16
SP - 37
EP - 48
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 1
ER -